Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

February 27, 2026

Study Completion Date

February 27, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

N-acetyl cysteine

600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.

DRUG

Placebo

Matching oral placebo tablet three times daily for 24 months.

Trial Locations (25)

10016

Weill Cornell Medicine, New York

14642

University of Rochester, Rochester

19140

Temple University, Philadelphia

22908

University of Virginia, Charlottesville

29425

Medical University of South Carolina, Charleston

30106

Piedmont Healthcare, Austell

37204

Lisa Lancaster, Nashville

43221

Ohio State University, Columbus

46202

Indiana University, Indianapolis

48109

University of Michigan, Ann Arbor

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

60153

Loyola University, Maywood

60637

University of Chicago, Chicago

66160

University of Kansas Medical Center, Kansas City

70112

Tulane University, New Orleans

75390

University of Texas Southwestern, Dallas

78229

University of Texas Health San Antonio, San Antonio

80045

University of Colorado, Aurora

84108

University of Utah Health, Salt Lake City

85724

University of Arizona, Tucson

90033

University of Southern California, Los Angeles

94305

Stanford University, Stanford

98195

University of Washington, Seattle

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

University of Virginia

OTHER

collaborator

University of Michigan

OTHER

collaborator

Pulmonary Fibrosis Foundation

OTHER

collaborator

University of Washington

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Three Lakes Foundation

UNKNOWN

lead

Fernando J Martinez

OTHER